Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation (final): Letermovir (Prevymis -- Merck Canada Inc.) indication : cytomegalovirus infection, prophylaxis

The CADTH Canadian Drug Expert Committee (CDEC) recommends that letermovir be reimbursed for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, June 2018
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Cytomegalovirus Infections / Drug Therapy
Acetates / Therapeutic Use
Antiviral Agents / Therapeutic Use
Quinazolines / Therapeutic Use
Drug Costs
Hematopoietic Stem Cell Transplantation
Antibiotic Prophylaxis / Methods
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that letermovir be reimbursed for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
Physical Description:1 PDF file (7 pages)

Similar Items